Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
"Micar Innovation" Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single action is assigned to 1 distinct examiner, COLEMAN, BRENDA LIBBY, who is the busiest examiner for the company with 1 pending case. The case is being prosecuted in 1 distinct art unit. This indicates a singular point of focus for the company's current pharmaceutical patent applications, requiring a highly specific and targeted prosecution strategy.
Because there is only 1 pending office action, the company's success in the Biotechnology & Pharmaceuticals area is currently tied to the decisions of COLEMAN, BRENDA LIBBY. This examiner's individual interpretation of the law and the specific standards of the 1 distinct art unit will be the primary factors in the case's outcome. Practitioners should focus on understanding this examiner's previous allowance rates and common objections. With 1 distinct examiner and 1 distinct art unit involved, the administrative burden is minimal, allowing for a concentrated effort on this single application. This focus ensures that the response to the 1 pending office action is as robust as possible, addressing all concerns raised within the specific pharmaceutical context.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| COLEMAN, BRENDA LIBBY | 1 | 74.8% | +15.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18852066 | PAN-CHEMOKINE ANTAGONISTS FOR USE IN TREATING CANCER AND IMMUNE DISORDERS | COLEMAN, BRENDA LIBBY | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18852066 | PAN-CHEMOKINE ANTAGONISTS FOR USE IN TREATING CANCER AND IMMUNE DISORDERS | COLEMAN, BRENDA LIBBY | 1624 | §112 | Non-Final OA | — | Pending | Sep 27, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial"Micar Innovation" Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Brenda Libby Coleman has the most, with 1 of "Micar Innovation" Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
